MedTrace Logo

Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation

NCT01319695 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-03-17

No results posted yet for this study

Summary

The use of corifollitropin alfa is superior in terms of pregnancy outcome parameters as compared to recombinant follicle stimulating hormone (FSH) during ovarian stimulation protocols in women undergoing in vitro fertilisation.

Conditions

Interventions

DRUG

corifollitropin alfa

100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing \>60 kg

DRUG

recombinant follicle stimulating hormone (FSH)

150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
36 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2016-07-31
Completion
2017-08-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01319695 on ClinicalTrials.gov